Published in World J Obstet Gynecol on May 10, 2016
Molecular portraits of human breast tumours. Nature (2000) 94.14
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82
Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A (2003) 59.17
Stem cells, cancer, and cancer stem cells. Nature (2001) 50.27
The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell (2008) 46.08
Epithelial-mesenchymal transitions in development and disease. Cell (2009) 39.17
Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A (2003) 34.68
Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer (2008) 18.08
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest (2011) 14.22
The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics (2006) 12.45
Triple-negative breast cancer. N Engl J Med (2010) 11.39
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol (2007) 10.49
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene (2010) 9.66
A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature (1994) 9.31
Gene-expression signatures in breast cancer. N Engl J Med (2009) 9.23
Ductal carcinoma in situ of the breast. N Engl J Med (2004) 6.63
Stem cells and cancer: two faces of eve. Cell (2006) 6.13
The increasing complexity of the cancer stem cell paradigm. Science (2009) 5.45
Identification of molecular apocrine breast tumours by microarray analysis. Oncogene (2005) 5.27
The CD44+/CD24- phenotype is enriched in basal-like breast tumors. Breast Cancer Res (2008) 4.63
Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell (2003) 4.56
Regulation of in situ to invasive breast carcinoma transition. Cancer Cell (2008) 4.46
Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med (2011) 4.25
Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin Cancer Res (2008) 3.83
Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells. Breast Cancer Res Treat (2001) 3.77
MCF10DCIS.com xenograft model of human comedo ductal carcinoma in situ. J Natl Cancer Inst (2000) 3.44
Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumors. Cancer Cell (2007) 3.44
Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med (2012) 3.38
Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res (2010) 3.19
How basal are triple-negative breast cancers? Int J Cancer (2008) 3.18
Increased lipogenesis in cancer cells: new players, novel targets. Curr Opin Clin Nutr Metab Care (2006) 3.09
Triple-negative breast cancer: distinguishing between basal and nonbasal subtypes. Clin Cancer Res (2009) 2.91
Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res (2008) 2.69
ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol Neoplasia (2009) 2.43
Basal cytokeratins and their relationship to the cellular origin and functional classification of breast cancer. Breast Cancer Res (2005) 2.43
Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol (2010) 2.42
An intraductal human-in-mouse transplantation model mimics the subtypes of ductal carcinoma in situ. Breast Cancer Res (2009) 2.37
Comparative genomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways. J Pathol (1999) 2.22
The microenvironment in breast cancer progression: biology and implications for treatment. Breast Cancer Res (2011) 2.22
Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res (2014) 2.18
Roots and stems: stem cells in cancer. Nat Med (2006) 2.13
Identification of a basal-like subtype of breast ductal carcinoma in situ. Hum Pathol (2007) 2.12
Analysis of loss of heterozygosity in 399 premalignant breast lesions at 15 genetic loci. J Natl Cancer Inst (1998) 2.06
Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod Pathol (2006) 1.96
Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol (2009) 1.91
Pharmacological inhibitors of mammalian fatty acid synthase suppress DNA replication and induce apoptosis in tumor cell lines. Cancer Res (1998) 1.83
Xenograft models of premalignant breast disease. J Mammary Gland Biol Neoplasia (2000) 1.79
Different genetic pathways in the evolution of invasive breast cancer are associated with distinct morphological subtypes. J Pathol (1999) 1.76
Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol (2014) 1.74
Breast cancer precursors revisited: molecular features and progression pathways. Histopathology (2010) 1.72
The molecular pathology of breast cancer progression. J Pathol (2010) 1.65
Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol (2010) 1.60
Classification of ductal carcinoma in situ by gene expression profiling. Breast Cancer Res (2006) 1.59
Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nat Med (2012) 1.55
Integrated genomic and transcriptomic analysis of ductal carcinoma in situ of the breast. Clin Cancer Res (2008) 1.50
Dynamic stromal-epithelial interactions during progression of MCF10DCIS.com xenografts. Int J Cancer (2007) 1.50
Downregulation of miR-140 promotes cancer stem cell formation in basal-like early stage breast cancer. Oncogene (2013) 1.41
Molecular characterisation of the tumour microenvironment in breast cancer. Eur J Cancer (2008) 1.39
Tumor cells can escape DNA-damaging cisplatin through DNA endoreduplication and reversible polyploidy. Cell Biol Int (2008) 1.38
Mechanism of apoptosis induced by the inhibition of fatty acid synthase in breast cancer cells. Cancer Res (2006) 1.35
Malignant precursor cells pre-exist in human breast DCIS and require autophagy for survival. PLoS One (2010) 1.35
The diagnosis and management of pre-invasive breast disease: ductal carcinoma in situ (DCIS) and atypical ductal hyperplasia (ADH)--current definitions and classification. Breast Cancer Res (2003) 1.27
Role of microRNAs in the regulation of breast cancer stem cells. J Mammary Gland Biol Neoplasia (2012) 1.25
Epithelial-to-mesenchymal transition: what is the impact on breast cancer stem cells and drug resistance. Cancer Treat Rev (2013) 1.25
A time- and matrix-dependent TGFBR3-JUND-KRT5 regulatory circuit in single breast epithelial cells and basal-like premalignancies. Nat Cell Biol (2014) 1.23
Cancer cell-associated MT1-MMP promotes blood vessel invasion and distant metastasis in triple-negative mammary tumors. Cancer Res (2011) 1.23
MicroRNAs transported by exosomes in body fluids as mediators of intercellular communication in cancer. Onco Targets Ther (2014) 1.22
Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile. Mod Pathol (2006) 1.22
Subtyping of triple-negative breast cancer: implications for therapy. Cancer (2014) 1.21
p63 Sustains self-renewal of mammary cancer stem cells through regulation of Sonic Hedgehog signaling. Proc Natl Acad Sci U S A (2015) 1.20
MT1-MMP is required for efficient tumor dissemination in experimental metastatic disease. Oncogene (2007) 1.19
Molecular subtyping of DCIS: heterogeneity of breast cancer reflected in pre-invasive disease. Br J Cancer (2010) 1.19
Dedifferentiation and reprogramming: origins of cancer stem cells. EMBO Rep (2014) 1.16
Cancer initiation and progression: involvement of stem cells and the microenvironment. Biochim Biophys Acta (2007) 1.16
The current state of breast cancer classification. Ann Oncol (2012) 1.16
Resveratrol suppresses growth of cancer stem-like cells by inhibiting fatty acid synthase. Breast Cancer Res Treat (2010) 1.11
p38γ mitogen-activated protein kinase contributes to oncogenic properties maintenance and resistance to poly (ADP-ribose)-polymerase-1 inhibition in breast cancer. Neoplasia (2011) 1.11
Results of conservative surgery and radiation for mammographically detected ductal carcinoma in situ (DCIS). Int J Radiat Oncol Biol Phys (1997) 1.09
Comedo-ductal carcinoma in situ: A paradoxical role for programmed cell death. Cancer Biol Ther (2008) 1.08
The role of tumor initiating cells in drug resistance of breast cancer: Implications for future therapeutic approaches. Drug Resist Updat (2010) 1.08
The transition from ductal carcinoma in situ to invasive breast cancer: the other side of the coin. Breast Cancer Res (2009) 1.07
Mammary carcinoma behavior is programmed in the precancer stem cell. Breast Cancer Res (2008) 1.07
Interobserver reproducibility of the Lagios nuclear grading system for ductal carcinoma in situ. Hum Pathol (1999) 1.06
Expression of membrane-type matrix metalloproteinase 1 (MT1-MMP) in tumor cells enhances pulmonary metastasis in an experimental metastasis assay. Cancer Res (1996) 1.03
Characterization of a stem-like subpopulation in basal-like ductal carcinoma in situ (DCIS) lesions. J Biol Chem (2013) 1.02
p63/MT1-MMP axis is required for in situ to invasive transition in basal-like breast cancer. Oncogene (2015) 1.02
Formation and role of exosomes in cancer. Cell Mol Life Sci (2014) 1.02
Long-term survival of women with basal-like ductal carcinoma in situ of the breast: a population-based cohort study. BMC Cancer (2010) 0.99
Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response. Breast Cancer Res (2015) 0.98
Therapeutic options for triple-negative breast cancers with defective homologous recombination. Biochim Biophys Acta (2009) 0.96
Elevated lipogenesis in epithelial stem-like cell confers survival advantage in ductal carcinoma in situ of breast cancer. Oncogene (2012) 0.95
The paradigm of mutant p53-expressing cancer stem cells and drug resistance. Carcinogenesis (2014) 0.92
A Molecular Portrait of High-Grade Ductal Carcinoma In Situ. Cancer Res (2015) 0.91
Comedo-DCIS is a precursor lesion for basal-like breast carcinoma: identification of a novel p63/Her2/neu expressing subgroup. Oncotarget (2013) 0.88
Targeting exosomes from preadipocytes inhibits preadipocyte to cancer stem cell signaling in early-stage breast cancer. Breast Cancer Res Treat (2015) 0.86
CUL4A contributes to the biology of basal-like breast tumors through modulation of cell growth and antitumor immune response. Oncotarget (2014) 0.85
The nuclear coactivator amplified in breast cancer 1 maintains tumor-initiating cells during development of ductal carcinoma in situ. Oncogene (2013) 0.84
Understanding tissue context influences on intratumour heterogeneity. Nat Cell Biol (2014) 0.84
Lymphocyte Invasion in IC10/Basal-Like Breast Tumors Is Associated with Wild-Type TP53. Mol Cancer Res (2014) 0.83
Regulation of DCIS to invasive breast cancer progression by Singleminded-2s (SIM2s). Oncogene (2012) 0.83